Derivatives of asimadoline with covalently bonded acids

Details Derivatives of asimadoline with covalently bonded acids Derivatives of asimadoline with covalently bonded acids

2011-03-29

2011-03-29

Jiang, Shaojia Anna (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C514S424000, C548S556000, C548S546000

Reexamination Certificate

active

07915228

ABSTRACT:
The present invention relates to derivatives of N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide with covalently bonded acids, and to the salts, solvates and prodrugs thereof, to the derivatives as medicaments, to the use of these derivatives for the preparation of a medicament, to the use of these derivatives for the preparation of a pharmaceutical composition, to a process for the preparation of the pharmaceutical compositions, to pharmaceutical compositions obtainable by this process, and to a process for the treatment of diseases which comprises the administration of the pharmaceutical composition.

REFERENCES:
patent: 4760069 (1988-07-01), Rzeszotarski et al.
patent: 4889860 (1989-12-01), Rzeszotarski et al.
patent: 5532266 (1996-07-01), Gottschlich et al.
patent: 5585500 (1996-12-01), Drauz et al.
patent: 5776972 (1998-07-01), Barber et al.
patent: 6060504 (2000-05-01), Stein et al.
patent: 6191126 (2001-02-01), Gamache
patent: 6303611 (2001-10-01), Zhang et al.
patent: 6344566 (2002-02-01), Bathe et al.
patent: 6569449 (2003-05-01), Stinchcomb et al.
patent: 2002/0025948 (2002-02-01), Banks et al.
patent: 2003/0036546 (2003-02-01), Clemens
patent: 2005/0176746 (2005-08-01), Weber et al.
patent: 2006/0122255 (2006-06-01), Wiesner et al.
patent: 2007/0179098 (2007-08-01), Wiesner et al.
patent: 4215213 (1993-11-01), None
patent: 19523502 (1997-01-01), None
patent: 19647538 (1998-05-01), None
patent: 0 569 802 (1993-11-01), None
patent: 09-020659 (1997-01-01), None
patent: 09-110830 (1997-04-01), None
patent: 2001-527062 (2001-12-01), None
patent: WO-99/33793 (1999-07-01), None
patent: WO-00/14065 (2000-03-01), None
patent: WO-01/98267 (2001-12-01), None
patent: WO-02/13801 (2002-02-01), None
patent: WO-02/58696 (2002-08-01), None
patent: WO-03/048113 (2003-06-01), None
patent: WO-03/097051 (2003-11-01), None
Merck Manual Online Medical Library: The Merck Manual of Diagnosis and Therapy “Introduction: Pain”; also available at http://www.merck.com/mmpe/print/sec16/ch209/ch209a.html; last viewed Apr. 20, 2010.
Merck Manual Online Medical Library: The Merck Manual for Healthcare Professionals “Pain”; also available at http://www.merck.com/mmpe/search.htm; last viewed Apr. 20, 2010.
Camilleri, M., Neurogastroenterol Motil “Novel pharmacology: asimadoline, a kappa-opioid agonist, and visceral sensation”, vol. 20, pp. 971-979 (2008).
Wolff, M. E., Burger's Medicinal Chemistry and Drug Discovery, Fifth Edition, vol. 1: Principles and Practice, pp. 975-977 (Mar. 1995).
Testa, Bernard, Biochemical Pharmacology “Prodrug resarch: futile or fertile?”, vol. 68, pp. 2097-2106 (2004).
Stella, V. J., Expert Opin. Ther. Patents “Prodrugs as therapeutics”, vol. 14, issue 3, pp. 277-280 (2004).
Ettmayer, Peter et al., Journal of Medicinal Chemistry “Lessons Learned from Marketed and Investigational Prodrugs”, vol. 47, issue 10, pp. 2393-2404 (2004).
Active ingredient [online], [retrieved on Nov. 22, 2006]. Retrieved from the Internet, URL; http://en.wikipedia.org/wiki/Active—pharmaceutical—ingredients>.
Cecil Textbook of Medicine, 20th ed. (1996) vol. 2, pp. 2050-2057.
Cecil Textbook of Medicine, 20th ed. (1996) vol. 2, pp. 1992-1996.
FDA mulls drug to slow late-stage Alzheimer's [online], [retrieved on Sep. 23, 2003]. Retrieved from the Internet, URL; http://www.cnn.com/2003/HEALTH/conditions/09/24/alzheimers.drug.ap/indexhtml>.
OBACH, Drug-Drug Interactions: An Important Negative Attribute in Drugs. Drugs of Today (2003) 39:301-338.
Lupus erythematosus[online], [retrieved on Dec. 28, 2006]. Retrieved from the Internet, URL; http://en.wikipedia.org/wiki/Lupus—erythematosus>.
Lupus [online], [retrieved on Jul. 6, 2007]. Retrieved from the Internet, URL; http://www.nlm.nih.gov/medlineplus/lupus.html>.
Cancer [online], [retrieved on Jul. 6, 2007]. Retrieved from the Internet, URL; http://en.wikipedia.org/wiki/Cancer>.
Cancer [online], [retrieved on Jul. 6, 2007]. Retrieved from the Internet, URL; http://www.nlm.nih.gov/medlineplus/cancer.html>.
Irritable Bowel Syndrome: Tips on Controlling Your Symptoms [online], [retrieved on Jul. 6, 2007]. Retrieved from the Internet, URL; http://familydoctor.org/online/famdocen/home/common/digestive/ disorders/112.html>.
Digestive Disorders [online], [retrieved on Jul. 6, 2007]. Retrieved from the Internet, URL; http://familydoctor.org/online/famdocen/home/common/digestive.html>.
Barber et al., British Journal of Pharmacology (Dec. 1994) 113(4):1317-1327.
Barber et al., Expert Opinion on Investigational New Drugs (1997) 6:1351-1368.
Gottschlich et al., Bioorganic & Medicinal Chemistry Letters (Jan. 1994) 4(5):677-682.
Hasler, “Disorders of Gastric Emptying,” in Textbook of Gastroenterology, 3rd edition, Yamada (ed.), 1999, p. 1346.
Johnson, Medical Hypotheses (1995) 45(5):491-497.
Mendelson, American Journal of Psychiatry (2001) 158(6):963-964.
Morley et al., American Journal of Clinical Nutrition (1985) 42(6):1175-1178.
Quigley, Expert Opinion on Pharmacotherapy (2000) 1:881-887.
Non-Final Office Action from U.S. Appl. No. 09/647,813, mailed on Jun. 4, 2001.
Amendment from U.S. Appl. No. 09/647,813, filed Sep. 4, 2001.
Notice of Allowance from U.S. Appl. No. 09/647,813, mailed on Sep. 20, 2001.
Restriction Requirement from U.S. Appl. No. 10/514,887, mailed on Jan. 19, 2006.
Amendment in Response to Non-Final Office Action from U.S. Appl. No. 10/514,887, filed May 19, 2006.
Restriction Requirement from U.S. Appl. No. 10/514,887, mailed on Jun. 30, 2006.
Response to Restriction Requirement from U.S. Appl. No. 10/514,887, filed Jul. 31, 2006.
Non-Final Office Action from U.S. Appl. No. 10/514,887, mailed on Sep. 12, 2006.
Amendment in Response to Non-Final Office Action from U.S. Appl. No. 10/514,887, filed Dec. 12, 2006.
Final Rejection from U.S. Appl. No. 10/514,887, mailed on Mar. 8, 2007.
Amendment After Final Action Under 37 CFR § 1.116, from U.S. Appl. No. 10/514,887, filed Sep. 10, 2007.
Notice of Allowance for U.S. Appl. No. 10/539,256, mailed on Feb. 19, 2008, 9 pages.
Non-Final Office Action from U.S. Appl. No. 11/732,309, mailed on Nov. 27, 2007.
Amendment in Response to Non-Final Office Action from U.S. Appl. No. 11/732,309, filed May 27, 2008.
Non-Final Office Action for U.S. Appl. No. 11/732,309, mailed on May 13, 2009, 12 pages.
Nolen et al., Pharmaceutical Research (1994) 11(12):1707-1711.
Nolen et al., Biopharmaceuticals & Drug Disposition (1997) 18(8):681-695.
Notificaiton of Reasons for Refusal (translation) for JP 2004-559717, mailed May 11, 2010, 3 pages.
Wermuth, The Practice of Medicinal Chemistry, Technomics, Inc. (1999) p. 276.

Affiliated with

Also associated with

Rating

Derivatives of asimadoline with covalently bonded acids does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Derivatives of asimadoline with covalently bonded acids, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Derivatives of asimadoline with covalently bonded acids will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2718514